Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Christiana Mantzourani, Sofia Vasilakaki, Velisaria-Eleni Gerogianni & George Kokotos. (2022) The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19. Expert Opinion on Drug Discovery 17:3, pages 231-246.
Read now
Read now
Articles from other publishers (33)
Kim Le, Shrute Kannappan, Truc Kim, Jung Heon Lee, Hye-Ra Lee & Kyeong Kyu Kim. (2023) Structural understanding of SARS-CoV-2 virus entry to host cells. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Cecilia Pozzi, Anne Vanet, Valeria Francesconi, Lorenzo Tagliazucchi, Giusy Tassone, Alberto Venturelli, Francesca Spyrakis, Marco MazzoranaMaria P. Costi & Michele Tonelli. (2023) Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective. Journal of Medicinal Chemistry 66:6, pages 3664-3702.
Crossref
Crossref
Aurélien F. A. Moumbock, Hoai T. T. Tran, Evelyn Lamy & Stefan Günther. (2022) BC‐11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS‐CoV‐2 host cell entry. Archiv der Pharmazie 356:1.
Crossref
Crossref
Taku Kinoshita, Masahiro Shinoda, Yasuhiro Nishizaki, Katsuya Shiraki, Yuji Hirai, Yoshiko Kichikawa, Kenji Tsushima, Masaharu Shinkai, Naoyuki Komura, Kazuo Yoshida, Yasutoshi Kido, Hiroshi Kakeya, Naoto Uemura & Junichi Kadota. (2022) A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study). BMC Medicine 20:1.
Crossref
Crossref
Els Tobback, Sophie Degroote, Sabine Buysse, Liesbeth Delesie, Lucas Van Dooren, Sophie Vanherrewege, Cyril Barbezange, Veronik Hutse, Marta Romano, Isabelle Thomas, Elizaveta Padalko, Steven Callens & Marie-Angélique De Scheerder. (2022) Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial. International Journal of Infectious Diseases 122, pages 628-635.
Crossref
Crossref
Thomas Boehm, Marion Alix, Karin Petroczi, Serhii Vakal, Elisabeth Gludovacz, Nicole Borth, Tiina A. Salminen & Bernd Jilma. (2022) Nafamostat is a Potent Human Diamine Oxidase Inhibitor Possibly Augmenting Hypersensitivity Reactions during Nafamostat Administration. Journal of Pharmacology and Experimental Therapeutics 382:2, pages 113-122.
Crossref
Crossref
Jonathan H. Shrimp, John Janiszewski, Catherine Z. Chen, Miao Xu, Kelli M. Wilson, Stephen C. Kales, Philip E. Sanderson, Paul Shinn, Rick Schneider, Zina Itkin, Hui Guo, Min Shen, Carleen Klumpp-Thomas, Samuel G. Michael, Wei Zheng, Anton Simeonov & Matthew D. Hall. (2022) Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19. ACS Infectious Diseases 8:6, pages 1191-1203.
Crossref
Crossref
Mostafa Abdelsalam, Ahmed M. Abd El Wahab, Mohammed Kamal Nassar, Emad Samaan, Ahmed Eldeep, Mohamed Abdalbary, Mona Tawfik, Marwa Saleh, Rasha Samir Shemies & Alaa Sabry. (2022)
Kidneys in
SARS‐CoV
‐2 era: A challenge of multiple faces
. Therapeutic Apheresis and Dialysis 26:3, pages 552-565.
Crossref
Crossref
Yuri Kosinsky, Kirill Peskov, Donald R. Stanski, Diana Wetmore & Joseph Vinetz. (2022) Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19. Microbiology Spectrum 10:2.
Crossref
Crossref
Farzaneh Sorouri, Zahra Emamgholipour, Maryam Keykhaee, Alireza Najafi, Loghman Firoozpour, Omid Sabzevari, Mohammad Sharifzadeh, Alireza Foroumadi & Mehdi Khoobi. (2022) The Situation of Small Molecules Targeting Key Proteins in combatting
SARS-CoV-2: Synthesis, Metabolic Pathway, Mechanism of Action, and
Potential Therapeutic Applications. Mini-Reviews in Medicinal Chemistry 22:2, pages 273-311.
Crossref
Crossref
Patrick Müller, Hannah Maus, Stefan Josef Hammerschmidt, Philip Maximilian Knaff, Volker Mailänder, Tanja Schirmeister & Christian Kersten. (2022) Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising
Therapeutic Strategy. Current Medicinal Chemistry 29:4, pages 635-665.
Crossref
Crossref
Lukas Wettstein, Frank Kirchhoff & Jan Münch. (2022) The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment. International Journal of Molecular Sciences 23:3, pages 1351.
Crossref
Crossref
Vikram Choudhary, Amisha Gupta, Rajesh Sharma & Hamendra Singh Parmar. (2021) Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2. Journal of Proteins and Proteomics 12:4, pages 257-270.
Crossref
Crossref
Lambert K. Sørensen, Jørgen B. Hasselstrøm, Jesper D. Gunst, Ole S. Søgaard & Mads Kjolby. (2021) Determination of camostat and its metabolites in human plasma – Preservation of samples and quantification by a validated UHPLC-MS/MS method. Clinical Biochemistry 96, pages 56-62.
Crossref
Crossref
Lukas Paulsson-Habegger, Andrew K. Snabaitis & Stephen P. Wren. (2021) Enzyme inhibition as a potential therapeutic strategy to treat COVID-19 infection. Bioorganic & Medicinal Chemistry 48, pages 116389.
Crossref
Crossref
Junsaku Kitagawa, Hayato Arai, Hiroyuki Iida, Jiro Mukai, Kenji Furukawa, Seitaro Ohtsu, Susumu Nakade, Tomohiro Hikima, Miwa Haranaka & Naoto Uemura. (2021) A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19. Clinical and Translational Science 14:5, pages 1967-1976.
Crossref
Crossref
Young Joo Sun, Gabriel Velez, Dylan E. Parsons, Kun Li, Miguel E. Ortiz, Shaunik Sharma, Paul B. McCrayJr.Jr., Alexander G. Bassuk & Vinit B. Mahajan. (2021) Structure-based phylogeny identifies avoralstat as a TMPRSS2 inhibitor that prevents SARS-CoV-2 infection in mice. Journal of Clinical Investigation 131:10.
Crossref
Crossref
Johanna Weiss, Gzona Bajraktari-Sylejmani & Walter Emil Haefeli. (2021) Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions. Chemico-Biological Interactions 338, pages 109428.
Crossref
Crossref
Markus Hoffmann, Heike Hofmann-Winkler, Joan C. Smith, Nadine Krüger, Prerna Arora, Lambert K. Sørensen, Ole S. Søgaard, Jørgen Bo Hasselstrøm, Michael Winkler, Tim Hempel, Lluís Raich, Simon Olsson, Olga Danov, Danny Jonigk, Takashi Yamazoe, Katsura Yamatsuta, Hirotaka Mizuno, Stephan Ludwig, Frank Noé, Mads Kjolby, Armin Braun, Jason M. Sheltzer & Stefan Pöhlmann. (2021) Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. EBioMedicine 65, pages 103255.
Crossref
Crossref
Peter Breining, Anne Lier Frølund, Jesper Falkesgaard Højen, Jesper Damsgaard Gunst, Nina B. Staerke, Eva Saedder, Manuel Cases‐Thomas, Paul Little, Lars Peter Nielsen, Ole S. Søgaard & Mads Kjolby. (2020) Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety. Basic & Clinical Pharmacology & Toxicology 128:2, pages 204-212.
Crossref
Crossref
Diego E. Escalante & David M. Ferguson. (2021) Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2. Medicinal Chemistry Research 30:2, pages 399-409.
Crossref
Crossref
Tim Hempel, Lluís Raich, Simon Olsson, Nurit P. Azouz, Andrea M. Klingler, Markus Hoffmann, Stefan Pöhlmann, Marc E. Rothenberg & Frank Noé. (2021) Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat. Chemical Science 12:3, pages 983-992.
Crossref
Crossref
A Chakraborty & A Diwan. (2020) Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment. Journal of Biomedical Research & Environmental Sciences 1:8, pages 431-438.
Crossref
Crossref
Markus Blaess, Lars Kaiser, Oliver Sommerfeld, Simone Rentschler, René Csuk & Hans-Peter Deigner. (2020) Rational Drug Repurposing: Focus on Lysosomotropism, Targets in Disease Process, Drug Profile, and Pulmonary Tissue Accumulation in SARS-CoV-2 Infection/COVID-19. Frontiers in Pharmacology 11.
Crossref
Crossref
Kiavash Hushmandi, Saied Bokaie, Mehrdad Hashemi, Ebrahim Rahmani Moghadam, Mehdi Raei, Farid Hashemi, Mahdi Bagheri, Solomon Habtemariam & Seyed Mohammad Nabavi. (2020) A review of medications used to control and improve the signs and symptoms of COVID-19 patients. European Journal of Pharmacology 887, pages 173568.
Crossref
Crossref
Jonathan H. Shrimp, Stephen C. Kales, Philip E. Sanderson, Anton Simeonov, Min Shen & Matthew D. Hall. (2020) An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19. ACS Pharmacology & Translational Science 3:5, pages 997-1007.
Crossref
Crossref
Markus Zeitlinger, Birgit C. P. Koch, Roger Bruggemann, Pieter De Cock, Timothy Felton, Maya Hites, Jennifer Le, Sonia Luque, Alasdair P. MacGowan, Deborah J. E. Marriott, Anouk E. Muller, Kristina Nadrah, David L. Paterson, Joseph F. Standing, João P. Telles, Michael Wölfl-Duchek, Michael Thy & Jason A. Roberts. (2020) Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. Clinical Pharmacokinetics 59:10, pages 1195-1216.
Crossref
Crossref
Dorothea Bestle, Miriam Ruth Heindl, Hannah Limburg, Thuy Van Lam van, Oliver Pilgram, Hong Moulton, David A Stein, Kornelia Hardes, Markus Eickmann, Olga Dolnik, Cornelius Rohde, Hans-Dieter Klenk, Wolfgang Garten, Torsten Steinmetzer & Eva Böttcher-Friebertshäuser. (2020) TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Science Alliance 3:9, pages e202000786.
Crossref
Crossref
Markus Blaess, Lars Kaiser, Martin Sauer, René Csuk & Hans-Peter Deigner. (2020) COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. International Journal of Molecular Sciences 21:14, pages 4953.
Crossref
Crossref
F. Hufert & M. Spiegel. (2020) Coronaviren: von der banalen Erkältung zum schweren LungenversagenCoronavirus: from common cold to severe pulmonary failure. Monatsschrift Kinderheilkunde 168:6, pages 488-501.
Crossref
Crossref
Bernhard N. Bohnert, Martina Menacher, Andrea Janessa, Matthias Wörn, Anja Schork, Sophie Daiminger, Hubert Kalbacher, Hans-Ulrich Häring, Christoph Daniel, Kerstin Amann, Florian Sure, Marko Bertog, Silke Haerteis, Christoph Korbmacher & Ferruh Artunc. (2018) Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome. Kidney International 93:1, pages 159-172.
Crossref
Crossref
Torsten Steinmetzer & Kornelia Hardes. 2018. Activation of Viruses by Host Proteases. Activation of Viruses by Host Proteases
279
325
.
Soon-Ho Kwon, Hye-Jin Shin, Ji-Myeong Park, Kyoung-Ryul Lee, Young-Jin Kim & Sang-Hoo Lee. (2011) Electrospray ionization tandem mass fragmentation pattern of camostat and its degradation product, 4-(4-guanidinobenzoyloxy)phenylacetic acid. Analytical Science and Technology 24:2, pages 78-84.
Crossref
Crossref